CU20150024A7 - QUINOLIN-6 AMINA Y QUINOLINA-7-AMINA DERIVADOS DE LA FÓRMULA (Id) y (Ir), Y SALES DERIVADAS - Google Patents
QUINOLIN-6 AMINA Y QUINOLINA-7-AMINA DERIVADOS DE LA FÓRMULA (Id) y (Ir), Y SALES DERIVADASInfo
- Publication number
- CU20150024A7 CU20150024A7 CU2015000024A CU20150024A CU20150024A7 CU 20150024 A7 CU20150024 A7 CU 20150024A7 CU 2015000024 A CU2015000024 A CU 2015000024A CU 20150024 A CU20150024 A CU 20150024A CU 20150024 A7 CU20150024 A7 CU 20150024A7
- Authority
- CU
- Cuba
- Prior art keywords
- group
- amina
- derived
- hydroxyl
- quinolina
- Prior art date
Links
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 206010063493 Premature ageing Diseases 0.000 abstract 1
- 208000032038 Premature aging Diseases 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a un compuesto (I) en donde: significa un grupo piridazina, pirimidina o pirazina, R independientemente representa un átomo de hidrógeno, átomo de halógeno o un grupo seleccionado de entre un grupo –CN, un grupo hidroxilo, un grupo –COOR1, un grupo fluoroalquilo de C1-C3, un grupo fluoroalcoxi de C1-C3, un grupo –NO2, un grupo –NriR2, un grupo alcoxi de C1-C4, un grupo fenoxi, y un grupo alquilo de C1-C3, el alquilo opcionalmente monosustituido por un grupo hidroxilo, n es 1, 2 o 3, n’ es 1 o 2, R’ es un átomo de hidrógeno, un átomo de halógeno o un grupo seleccionado entre un grupo alquilo de C1-C3, un grupo hidroxilo, un grupo –COOR1, un grupo –NO2, un grupo –NR1R2, un grupo morfolinilo o morfolino, un grupo Nmetilpiperazinilo, un grupo fluoroalquilo de C1-C3, un grupo alcoxi de C1-C4, y un grupo –CN, Z es N o C, Y es N o C, Z es N o C, W es N o C, T es N o C, U es N o C, para utilizarse como un agente para la prevención, inhibición o tratamiento de afecciones patológicas o no patológicas involucradas con envejecimiento prematuro. Algunos de los compuestos son nuevos y también forman parte de la invención.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18654409P | 2009-06-12 | 2009-06-12 | |
| US18655209P | 2009-06-12 | 2009-06-12 | |
| EP09162630A EP2261214A1 (en) | 2009-06-12 | 2009-06-12 | Compounds useful to treat premature aging and in particular progeria |
| EP20090305540 EP2266972A1 (en) | 2009-06-12 | 2009-06-12 | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
| PCT/IB2010/052652 WO2010143170A2 (en) | 2009-06-12 | 2010-06-14 | Compounds useful for treating premature aging and in particular progeria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20150024A7 true CU20150024A7 (es) | 2015-09-29 |
| CU24245B1 CU24245B1 (es) | 2017-02-02 |
Family
ID=43309298
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2011000230A CU24093B1 (es) | 2009-06-12 | 2010-06-14 | Derivados de isoquinolina vinculados al proceso de empalme celular |
| CUP2011000229A CU24124B1 (es) | 2009-06-12 | 2010-06-14 | N-fenil-naftalen-2-aminas sustituidas para el tratamiento del cáncer. |
| CU2011000228A CU24461B1 (es) | 2009-06-12 | 2010-06-14 | Compuestos útiles para tratar envejecimiento prematuro y en particular progeria |
| CUP2015000024A CU24245B1 (es) | 2009-06-12 | 2010-06-14 | QUINOLIN-6 AMINA Y QUINOLINA-7-AMINA DERIVADOS DE LA FÓRMULA (Id) y (Ir), Y SALES DERIVADAS |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2011000230A CU24093B1 (es) | 2009-06-12 | 2010-06-14 | Derivados de isoquinolina vinculados al proceso de empalme celular |
| CUP2011000229A CU24124B1 (es) | 2009-06-12 | 2010-06-14 | N-fenil-naftalen-2-aminas sustituidas para el tratamiento del cáncer. |
| CU2011000228A CU24461B1 (es) | 2009-06-12 | 2010-06-14 | Compuestos útiles para tratar envejecimiento prematuro y en particular progeria |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US20120329796A1 (es) |
| EP (6) | EP2440546B1 (es) |
| JP (8) | JP6041671B2 (es) |
| KR (14) | KR101973348B1 (es) |
| CN (13) | CN102625804B (es) |
| AU (3) | AU2010258294B2 (es) |
| BR (5) | BRPI1010772B8 (es) |
| CA (5) | CA3070823C (es) |
| CU (4) | CU24093B1 (es) |
| DK (4) | DK3517534T3 (es) |
| ES (4) | ES2940885T3 (es) |
| FI (3) | FI2440547T3 (es) |
| HR (3) | HRP20230143T1 (es) |
| HU (2) | HUE045548T2 (es) |
| LT (1) | LT2440547T (es) |
| MX (10) | MX364989B (es) |
| PL (4) | PL2440547T3 (es) |
| PT (4) | PT2440546T (es) |
| RU (1) | RU2567752C2 (es) |
| SI (1) | SI2440547T1 (es) |
| TR (1) | TR201910781T4 (es) |
| WO (3) | WO2010143168A2 (es) |
| ZA (2) | ZA201109032B (es) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
| HRP20191460T1 (hr) * | 2009-06-12 | 2019-11-15 | Abivax | Spojevi korisni za liječenje raka |
| CN102625804B (zh) * | 2009-06-12 | 2015-04-08 | Abivax公司 | 用于治疗aids的化合物 |
| DK2473504T3 (en) | 2009-09-03 | 2015-03-16 | Bioenergenix | Heterocyclic Compounds for Inhibition of Passover |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| EP2465502A1 (en) * | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| WO2012094462A2 (en) | 2011-01-05 | 2012-07-12 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| US8916561B2 (en) | 2011-03-02 | 2014-12-23 | Bioenergenix, Llc | Substituted quinoxaline compounds for the inhibition of PASK |
| WO2012119046A2 (en) | 2011-03-02 | 2012-09-07 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| FR2987627B1 (fr) | 2012-03-05 | 2016-03-18 | Splicos | Utilisation de rbm39 comme biomarqueur |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| EP2863920B1 (en) * | 2012-06-20 | 2023-03-22 | Eutropics Pharmaceuticals, Inc. | Quinoline derivatives for use in the tratment of breast cancer |
| US9145411B2 (en) | 2012-08-02 | 2015-09-29 | Asana Biosciences, Llc | Substituted amino-pyrimidine derivatives |
| US9487526B2 (en) | 2012-08-13 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Quinoxaline derivatives as GPR6 modulators |
| WO2014065209A1 (ja) * | 2012-10-23 | 2014-05-01 | 日本曹達株式会社 | ピリジン化合物またはその塩、有害生物防除剤、殺虫剤または殺ダニ剤、および外部寄生虫防除剤 |
| EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| GB201301571D0 (en) * | 2012-11-27 | 2013-03-13 | Fundanci N Pedro Barri De La Maza | Product and use |
| US20140194465A1 (en) * | 2013-01-04 | 2014-07-10 | Novarx Corporation | Compositions for treatment of cancer |
| EP2757161A1 (en) * | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| CA2916623C (en) * | 2013-07-05 | 2021-09-14 | Abivax | Bicyclic compounds useful for treating diseases caused by retroviruses |
| US9879014B2 (en) | 2013-07-12 | 2018-01-30 | Kyoto University | Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease |
| US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
| AU2014342269B2 (en) | 2013-10-30 | 2020-02-27 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
| JO3466B1 (ar) | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
| JP6526034B2 (ja) | 2014-02-14 | 2019-06-05 | 武田薬品工業株式会社 | Ｇｐｒ６のピリドピラジンモジュレーター |
| US10736900B2 (en) | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
| BR112016022056B1 (pt) | 2014-03-26 | 2023-04-11 | Astex Therapeutics Limited | Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| EP2974729A1 (en) * | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
| WO2016120495A1 (en) | 2015-01-30 | 2016-08-04 | Centre National De La Recherche Scientifique (Cnrs) | Delta133p53beta and delta133p53gamma isoforms are biomarkers of cancer stem cells |
| TWI719960B (zh) | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| EP3059591A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
| EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
| EP3059236A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| HUE050567T2 (hu) | 2015-09-23 | 2020-12-28 | Janssen Pharmaceutica Nv | Triciklusos heterociklusok rák kezelésére |
| WO2017050865A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| US10646465B2 (en) | 2015-12-17 | 2020-05-12 | Biokine Therapeutics Ltd. | Small molecules against cancer |
| US11129824B2 (en) | 2015-12-17 | 2021-09-28 | Biokine Therapeutics Ltd. | Small molecules for inhibiting chemokine activity and/or cancer cells growth |
| WO2017134098A1 (en) * | 2016-02-03 | 2017-08-10 | Janssen Pharmaceutica Nv | Tau pet imaging ligands |
| WO2017158201A1 (en) | 2016-03-18 | 2017-09-21 | Ratiopharm Gmbh | Process for preparing quinolin-2-yl-phenylamine derivatives and their salts |
| EP3484528B1 (en) | 2016-07-18 | 2020-11-25 | Janssen Pharmaceutica NV | Tau pet imaging ligands |
| AR112027A1 (es) | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| US10323289B2 (en) * | 2017-06-26 | 2019-06-18 | Institut Pasteur | Treatments to eliminate HIV reservoirs and reduce viral load |
| JP6965432B2 (ja) * | 2017-08-29 | 2021-11-10 | チュラポーン ファンデーション | キノリンおよびナフチリジンの誘導体および組成物 |
| US12528810B2 (en) * | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| WO2019186277A1 (en) | 2018-03-28 | 2019-10-03 | Institut Pasteur | Ultrasensitive hiv-1 p24 detection assay |
| EP3594206A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| EP3594205A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| WO2020128033A1 (en) | 2018-12-20 | 2020-06-25 | Institut Pasteur | Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells |
| EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| EP3669874A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
| CA3090315C (en) | 2019-05-15 | 2023-09-19 | Biokine Therapeutics Ltd. | 8-phenoxy-quinolinone derivatives for treating cancer, inhibiting chemokine activity and/or inducing cell death |
| EP3999493B1 (en) | 2019-07-19 | 2023-12-20 | Abivax | Aryl-n-aryl derivatives for treating a rna virus infection |
| EP3858815A1 (en) | 2020-01-31 | 2021-08-04 | Abivax | Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| CA3164700A1 (en) * | 2020-01-31 | 2021-08-05 | Abivax | Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| EP3858336A1 (en) | 2020-01-31 | 2021-08-04 | Abivax | Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| BR112022018793A2 (pt) | 2020-03-20 | 2022-11-29 | Abivax | Uso de um composto de fórmula (i) ou (ii) para tratar ou previnir uma infecção por coronaviridae e condições relacionadas, composição farmacêutica e medicamento compreendendo os mesmos, uso de um mirna como um biomarcador de uma infecção por coronaviridae, e método para avaliar uma infecção por coronaviridae |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| IL299612A (en) | 2020-07-02 | 2023-03-01 | Incyte Corp | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| EP4063351A1 (en) | 2021-03-26 | 2022-09-28 | Abivax | Preparation method of quinoline derivative compounds |
| WO2022247920A1 (zh) | 2021-05-27 | 2022-12-01 | 江苏恒瑞医药股份有限公司 | 喹啉胺类化合物、其制备方法及其在医药上的应用 |
| KR20230072900A (ko) | 2021-11-18 | 2023-05-25 | 동우 화인켐 주식회사 | 마이크로 led 구조체 및 이의 제조방법 |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| TW202333698A (zh) * | 2022-01-24 | 2023-09-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 喹啉胺類化合物、其製備方法及其在醫藥上的應用 |
| EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
| IL315647A (en) | 2022-03-17 | 2024-11-01 | Incyte Corp | Tricyclic urea compounds as Jak2 and 617f inhibitors |
| CN118027024A (zh) * | 2022-11-14 | 2024-05-14 | 南京同诺康医药科技有限公司 | 吡啶并[1,2-a]嘧啶-4-酮衍生物及其制备方法和用途 |
| TW202436296A (zh) | 2022-11-25 | 2024-09-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喹啉胺類化合物晶型及其製備方法 |
| WO2025027388A1 (en) | 2023-08-01 | 2025-02-06 | Abivax | Obefazimod for treatment of ulcerative colitis |
| IL326865A (en) * | 2023-08-30 | 2026-04-01 | Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd | Compound for regulating activity of microrna-124 |
| EP4785941A1 (en) | 2025-01-31 | 2026-08-05 | Abivax | Combination of obefazimod and its derivatives with a alpha4beta7 anti-integrin |
| EP4785940A1 (en) | 2025-01-31 | 2026-08-05 | Abivax | Combination of obefazimod and its derivatives with a tnf alpha-inhibitor |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR400973A (fr) | 1909-03-19 | 1909-08-13 | Jean Victor Massillon | Nouveau sertisseur à main pour la fabrication des cartouches |
| GB585362A (en) | 1944-08-31 | 1947-02-05 | Francis Henry Swinden Curd | New heterocyclic compounds |
| BE486034A (es) | 1947-11-28 | |||
| DE958647C (de) | 1952-12-28 | 1957-02-21 | Hoechst Ag | Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen |
| FR2387229A1 (fr) | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
| FR2627493B1 (fr) | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
| FR2645861A1 (fr) | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| AU763750B2 (en) | 1999-04-05 | 2003-07-31 | City Of Hope | Novel inhibitors of formation of advanced glycation endproducts (AGE's) |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| DE10013318A1 (de) * | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
| WO2002074726A2 (en) | 2001-01-22 | 2002-09-26 | Memory Pharmaceuticals Corporation | Aniline derivatives useful as phosphodiesterase 4 inhibitors |
| JP2005531574A (ja) | 2002-05-22 | 2005-10-20 | アムジエン・インコーポレーテツド | 痛みの治療にバニロイド受容体リガンドとして使用するためのアミノ−ピリジン、−ピリジンおよびピリダジン誘導体 |
| AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| MXPA05000827A (es) * | 2002-07-19 | 2005-08-29 | Memory Pharm Corp | Inhibidores de fosfodiesterasa 4, incluyendo analogos de anilina y difenilamina n-sustituidos. |
| FR2849474B3 (fr) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | Installation de transformation de l'energie cinetique d'un fluide en energie electrique |
| WO2004078731A1 (en) | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Quinoline-carboxylic acids and the derivatives thereof, a focused library |
| MXPA05009722A (es) * | 2003-03-10 | 2006-03-09 | Schering Corp | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. |
| FR2859475A1 (fr) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| WO2005037285A1 (en) * | 2003-10-16 | 2005-04-28 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
| KR101190912B1 (ko) * | 2003-11-19 | 2012-10-12 | 어레이 바이오파마 인크. | Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법 |
| EP1814856A1 (en) * | 2004-11-12 | 2007-08-08 | Galapagos N.V. | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
| EP1853265B1 (en) | 2005-01-28 | 2016-01-27 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Farnesyltransferase inhibitors for use in the treatment of laminopathies, cellular aging and atherosclerosis |
| WO2007000876A1 (ja) * | 2005-06-29 | 2007-01-04 | Adeka Corporation | 樹脂添加剤組成物及びその樹脂組成物 |
| FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
| WO2008008234A1 (en) * | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| ES2547303T3 (es) * | 2007-01-19 | 2015-10-05 | Ardea Biosciences, Inc. | Inhibidores de MEK |
| FR2912745A1 (fr) | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
| US20100249184A1 (en) * | 2007-03-16 | 2010-09-30 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
| US8222634B2 (en) | 2007-05-17 | 2012-07-17 | Lg Chem, Ltd. | Anthracene derivatives and organic electronic device using the same |
| UY31272A1 (es) * | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| WO2009023844A2 (en) | 2007-08-15 | 2009-02-19 | Memory Pharmaceuticals Corporation | 3' substituted compounds having 5-ht6 receptor affinity |
| WO2009029617A1 (en) * | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors |
| KR100974562B1 (ko) * | 2007-12-31 | 2010-08-06 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자 |
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| JP2012514586A (ja) * | 2009-01-05 | 2012-06-28 | フラウンホーファーゲゼルシャフト ツール フォルデルング デル アンゲヴァンテン フォルシユング エー．フアー． | Ｉｌ−２１およびｉｌ−２１変異体に基づく抗体欠乏性疾患を治療するための手段および方法 |
| BRPI1007222A2 (pt) * | 2009-01-06 | 2016-02-23 | Inserm Inst Nat De La Santé Et De La Rech Médicale | agente de depleção de células b para tratamento de aterosclerose |
| US20120172617A1 (en) * | 2009-01-06 | 2012-07-05 | Werner Bonrath | resveratrol intermediates dal |
| CN102625804B (zh) | 2009-06-12 | 2015-04-08 | Abivax公司 | 用于治疗aids的化合物 |
| HRP20191460T1 (hr) * | 2009-06-12 | 2019-11-15 | Abivax | Spojevi korisni za liječenje raka |
| EP2266972A1 (en) | 2009-06-12 | 2010-12-29 | Splicos | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
| WO2010151755A2 (en) | 2009-06-25 | 2010-12-29 | The Brigham And Women's Hospital, Inc. | TREATMENT OF INFLAMMATORY DISEASES USING miR-124 |
| EP2465502A1 (en) | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| US20150272959A1 (en) | 2012-10-04 | 2015-10-01 | Oyagen, Inc. | Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| JP2015120566A (ja) * | 2013-12-20 | 2015-07-02 | ニチユ三菱フォークリフト株式会社 | 荷役車両 |
-
2010
- 2010-06-14 CN CN201080032045.7A patent/CN102625804B/zh active Active
- 2010-06-14 KR KR1020187025624A patent/KR101973348B1/ko active Active
- 2010-06-14 AU AU2010258294A patent/AU2010258294B2/en not_active Ceased
- 2010-06-14 BR BRPI1010772A patent/BRPI1010772B8/pt active IP Right Grant
- 2010-06-14 MX MX2015016293A patent/MX364989B/es unknown
- 2010-06-14 EP EP10728369.9A patent/EP2440546B1/en active Active
- 2010-06-14 PT PT107283699T patent/PT2440546T/pt unknown
- 2010-06-14 CN CN202110307700.5A patent/CN113004249A/zh active Pending
- 2010-06-14 CN CN201510023109.1A patent/CN104844510B/zh not_active Expired - Fee Related
- 2010-06-14 US US13/377,753 patent/US20120329796A1/en not_active Abandoned
- 2010-06-14 SI SI201032127T patent/SI2440547T1/sl unknown
- 2010-06-14 KR KR1020127000915A patent/KR101789275B1/ko active Active
- 2010-06-14 CU CU2011000230A patent/CU24093B1/es active IP Right Grant
- 2010-06-14 CN CN201710158473.8A patent/CN106928205B/zh not_active Expired - Fee Related
- 2010-06-14 AU AU2010258214A patent/AU2010258214B2/en active Active
- 2010-06-14 HR HRP20230143TT patent/HRP20230143T1/hr unknown
- 2010-06-14 KR KR1020177021820A patent/KR101863021B1/ko not_active Expired - Fee Related
- 2010-06-14 MX MX2011013120A patent/MX338823B/es active IP Right Grant
- 2010-06-14 EP EP10728368.1A patent/EP2440545B1/en active Active
- 2010-06-14 BR BRPI1012892A patent/BRPI1012892B8/pt active IP Right Grant
- 2010-06-14 CN CN201910120757.7A patent/CN109776496B/zh not_active Expired - Fee Related
- 2010-06-14 JP JP2012514585A patent/JP6041671B2/ja not_active Expired - Fee Related
- 2010-06-14 CA CA3070823A patent/CA3070823C/en active Active
- 2010-06-14 CA CA2764027A patent/CA2764027C/en active Active
- 2010-06-14 CU CUP2011000229A patent/CU24124B1/es active IP Right Grant
- 2010-06-14 KR KR1020197004606A patent/KR102016891B1/ko not_active Expired - Fee Related
- 2010-06-14 KR KR1020197004608A patent/KR102016893B1/ko not_active Expired - Fee Related
- 2010-06-14 DK DK19157827.7T patent/DK3517534T3/da active
- 2010-06-14 KR KR1020197004604A patent/KR102016889B1/ko not_active Expired - Fee Related
- 2010-06-14 US US13/377,760 patent/US9145367B2/en active Active
- 2010-06-14 KR KR1020197004605A patent/KR102016890B1/ko not_active Expired - Fee Related
- 2010-06-14 CN CN201510023124.6A patent/CN104844570B/zh not_active Expired - Fee Related
- 2010-06-14 FI FIEP10757474.1T patent/FI2440547T3/fi active
- 2010-06-14 MX MX2016003039A patent/MX359575B/es unknown
- 2010-06-14 WO PCT/IB2010/052650 patent/WO2010143168A2/en not_active Ceased
- 2010-06-14 HU HUE10728368A patent/HUE045548T2/hu unknown
- 2010-06-14 BR BR122019013686-6A patent/BR122019013686B1/pt active IP Right Grant
- 2010-06-14 ES ES10728369T patent/ES2940885T3/es active Active
- 2010-06-14 ES ES10728368T patent/ES2736198T3/es active Active
- 2010-06-14 MX MX2018009425A patent/MX373120B/es unknown
- 2010-06-14 PL PL10757474.1T patent/PL2440547T3/pl unknown
- 2010-06-14 FI FIEP19157827.7T patent/FI3517534T3/fi active
- 2010-06-14 TR TR2019/10781T patent/TR201910781T4/tr unknown
- 2010-06-14 CU CU2011000228A patent/CU24461B1/es unknown
- 2010-06-14 MX MX2015016291A patent/MX364279B/es unknown
- 2010-06-14 JP JP2012514587A patent/JP5905385B2/ja active Active
- 2010-06-14 CN CN201410106644.9A patent/CN103948594B/zh not_active Expired - Fee Related
- 2010-06-14 HR HRP20240582TT patent/HRP20240582T1/hr unknown
- 2010-06-14 MX MX2011013119A patent/MX353776B/es active IP Right Grant
- 2010-06-14 CU CUP2015000024A patent/CU24245B1/es unknown
- 2010-06-14 CN CN201510021597.2A patent/CN104945379B/zh not_active Expired - Fee Related
- 2010-06-14 EP EP22193611.5A patent/EP4198022A1/en active Pending
- 2010-06-14 AU AU2010258295A patent/AU2010258295B2/en active Active
- 2010-06-14 PT PT191578277T patent/PT3517534T/pt unknown
- 2010-06-14 ES ES10757474T patent/ES2938532T3/es active Active
- 2010-06-14 ES ES19157827T patent/ES2985082T3/es active Active
- 2010-06-14 BR BR122019013687A patent/BR122019013687B1/pt active IP Right Grant
- 2010-06-14 DK DK10728368.1T patent/DK2440545T3/da active
- 2010-06-14 KR KR1020187025625A patent/KR101982462B1/ko not_active Expired - Fee Related
- 2010-06-14 KR KR1020127000916A patent/KR101769616B1/ko not_active Expired - Fee Related
- 2010-06-14 LT LTEPPCT/IB2010/052651T patent/LT2440547T/lt unknown
- 2010-06-14 CA CA2965791A patent/CA2965791C/en active Active
- 2010-06-14 JP JP2012514586A patent/JP5826745B2/ja active Active
- 2010-06-14 RU RU2011149571/04A patent/RU2567752C2/ru active
- 2010-06-14 CA CA2764026A patent/CA2764026C/en active Active
- 2010-06-14 HU HUE10757474A patent/HUE061262T2/hu unknown
- 2010-06-14 FI FIEP10728369.9T patent/FI2440546T3/fi active
- 2010-06-14 PT PT107574741T patent/PT2440547T/pt unknown
- 2010-06-14 KR KR1020197004607A patent/KR102016892B1/ko not_active Expired - Fee Related
- 2010-06-14 PT PT10728368T patent/PT2440545T/pt unknown
- 2010-06-14 EP EP19157824.4A patent/EP3521283B1/en active Active
- 2010-06-14 KR KR1020177031675A patent/KR101897221B1/ko not_active Expired - Fee Related
- 2010-06-14 KR KR1020187025623A patent/KR101982461B1/ko not_active Expired - Fee Related
- 2010-06-14 DK DK10757474.1T patent/DK2440547T3/da active
- 2010-06-14 MX MX2015016290A patent/MX364282B/es unknown
- 2010-06-14 CN CN201510020820.1A patent/CN104945378B/zh not_active Expired - Fee Related
- 2010-06-14 CN CN201710158474.2A patent/CN106928194B/zh not_active Expired - Fee Related
- 2010-06-14 DK DK10728369.9T patent/DK2440546T3/da active
- 2010-06-14 CN CN201080032036.8A patent/CN102574835B/zh not_active Expired - Fee Related
- 2010-06-14 EP EP10757474.1A patent/EP2440547B1/en active Active
- 2010-06-14 KR KR1020187025626A patent/KR101982463B1/ko not_active Expired - Fee Related
- 2010-06-14 MX MX2016007353A patent/MX367601B/es unknown
- 2010-06-14 PL PL10728369.9T patent/PL2440546T3/pl unknown
- 2010-06-14 WO PCT/IB2010/052652 patent/WO2010143170A2/en not_active Ceased
- 2010-06-14 US US13/377,745 patent/US20120277230A1/en not_active Abandoned
- 2010-06-14 KR KR1020127000914A patent/KR20120051643A/ko not_active Ceased
- 2010-06-14 WO PCT/IB2010/052651 patent/WO2010143169A2/en not_active Ceased
- 2010-06-14 MX MX2015016292A patent/MX364280B/es unknown
- 2010-06-14 PL PL19157827.7T patent/PL3517534T3/pl unknown
- 2010-06-14 HR HRP20230248TT patent/HRP20230248T1/hr unknown
- 2010-06-14 PL PL10728368T patent/PL2440545T3/pl unknown
- 2010-06-14 CN CN201080032055.0A patent/CN102596935B/zh not_active Expired - Fee Related
- 2010-06-14 BR BRPI1010768A patent/BRPI1010768C8/pt not_active IP Right Cessation
- 2010-06-14 EP EP19157827.7A patent/EP3517534B1/en active Active
- 2010-06-14 MX MX2011013122A patent/MX340095B/es active IP Right Grant
- 2010-06-14 CN CN201710122014.4A patent/CN106905232B/zh not_active Expired - Fee Related
- 2010-06-14 CA CA2764024A patent/CA2764024C/en active Active
-
2011
- 2011-12-08 ZA ZA2011/09032A patent/ZA201109032B/en unknown
- 2011-12-08 ZA ZA2011/09031A patent/ZA201109031B/en unknown
-
2013
- 2013-11-22 US US14/087,762 patent/US9108919B2/en active Active
-
2014
- 2014-04-18 US US14/256,334 patent/US9908869B2/en not_active Expired - Fee Related
-
2015
- 2015-04-27 JP JP2015090437A patent/JP2015155453A/ja active Pending
- 2015-06-15 JP JP2015120568A patent/JP6158251B2/ja active Active
- 2015-06-15 JP JP2015120567A patent/JP6158250B2/ja not_active Expired - Fee Related
- 2015-06-15 JP JP2015120566A patent/JP2015187150A/ja not_active Withdrawn
- 2015-07-01 US US14/789,250 patent/US10017498B2/en active Active
- 2015-07-01 US US14/789,149 patent/US9637475B2/en active Active
-
2019
- 2019-10-18 JP JP2019191500A patent/JP7042245B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011013119A (es) | Compuestos utiles para tratar cancer. | |
| PE20121048A1 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| MX2021006754A (es) | Derivados de quinoleina para el tratamiento de enfermedades inflamatorias. | |
| AR062074A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa | |
| AR094378A1 (es) | Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral | |
| CU20170026A7 (es) | Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf | |
| MX2020000404A (es) | Inhibidores de tirosina quinasa de bazo (syk). | |
| GT200500242A (es) | Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas | |
| CU20210004A7 (es) | Derivados de fenil/piridil-n-fenil/piridilo para el tratamiento de una infección por virus de ácido ribonucleico (arn) y proceso para su preparación | |
| PE20240022A1 (es) | Derivados de fosforo como nuevos inhibidores de sos1 | |
| BRPI1009212B8 (pt) | Composto de piperazina capaz de inibir a prostaglandina d sintase, seus usos e composição farmacêutica | |
| NI200900164A (es) | COMPUESTOS AMINO- 5 -[ -4- (DIFLUOROMETOXI) FENIL SUSTITUIDO] -5- FENILIMIDAZOLONA COMO INHIBIDORES DE Beta - SECRETASA. | |
| CU24674B1 (es) | Derivados de fenil-n-quinolina y proceso para su preparación | |
| MX2019008390A (es) | Compuestos utiles para tratar cancer. | |
| AR088552A1 (es) | Composicion y metodo para controlar fitoenfermedades | |
| AR088553A1 (es) | Composicion y metodo para controlar fitoenfermedades | |
| MX2018010535A (es) | Derivado de 5-metil-6-fenil-4,5-dihidro-2h-piridazin-3-ona. | |
| AR110150A1 (es) | Procesos para la preparación de inhibidores de tph1 | |
| MX377665B (es) | Metodo para preparar oxisulfuro y derivados fluorados mediante sulfinacion. | |
| AR094381A1 (es) | Derivados benzodioxano-piperidina y sus aplicaciones terapéuticas para el tratamiento de trastornos neuropsiquiátricos | |
| AR076276A1 (es) | Derivados de n-[(7-aza-biciclo[2.2.1]hept-1-il)-aril-metil]-benzamida, su prepara-cion y su aplicacion en terapeutica | |
| MX2021011902A (es) | Agente antimicrobiano. | |
| PL408240A1 (pl) | Mono-chloro pochodne 9,10-antrachinonu i sposób otrzymywania mono-chloro pochodnych 9,10-antrachinonu |